Significantly longer progression-free survival seen among patients with previously untreated, PD-L1 advanced or metastatic ...

A groundbreaking study reveals that sacituzumab govitecan and pembrolizumab significantly enhance survival in untreated metastatic triple-negative breast cancer patients.

A new study has found that a commonly prescribed anti-nausea medication is associated with a better prognosis for women with early-stage breast cancer, particularly triple-negative breast cancer. The ...

March 28, 2007 — A new study clearly reveals the survival disadvantage for the so-called "triple-negative" subtype of breast cancer compared with other types of breast cancer. These tumors test ...

Our stories are reviewed by medical professionals to ensure you get the most accurate and useful information about your health and wellness. For more information, visit our medical review board. This ...

VANCOUVER, Washington, Nov. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal ...

Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was observed in patients treated with ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary ...

Triple-negative breast cancer lacks key receptors, requiring chemotherapy, immunotherapy, surgery, and radiation, with treatment tailored to cancer stage. Early-stage TNBC treatment often involves ...

By targeting proteins used to splice genes, UC San Diego researchers have unlocked a new approach to treating triple-negative ...